ArticleMolecular cancer therapeutics2018
Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response.
Abstract read
In one paragraph
Article in Molecular cancer therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 66 citations in OpenAlex.
- Dual Targeting of EZH2 and LSD1 Suppresses Hepatocellular Carcinoma via Disruption of Sonic Hedgehog Signaling.International journal of molecular sciences · 2026Article
- LSD1 Performs Demethylase-Independent and Context-Specific Roles in Ewing Sarcoma.Cancer research communications · 2026Article
- Rewiring the Fusion Oncoprotein EWSR1::FLI1 in Ewing Sarcoma with Bivalent Small Molecules.Journal of the American Chemical Society · 2025Article
- LSD1 Performs Demethylase-Independent and Context-Specific Roles in Ewing Sarcoma.bioRxiv : the preprint server for biology · 2025Article
- Article
- Targeting developmental vulnerabilities in childhood sarcomas.Cancer metastasis reviews · 2025Review
- Seclidemstat (SP-2577) Induces Transcriptomic Reprogramming and Cytotoxicity in Multiple Fusion-Positive Sarcomas.Cancer research communications · 2025Article
- Metabolic traits shape responses to LSD1-directed therapy in glioblastoma tumor-initiating cells.Science advances · 2025Article
- Inhibition of LSD1 via SP2509 attenuated the progression of rheumatoid arthritis.Immunologic research · 2024Article
- Seclidemstat blocks the transcriptional function of multiple FET-fusion oncoproteins.bioRxiv : the preprint server for biology · 2024Article
- KDM3B inhibitors disrupt the oncogenic activity of PAX3-FOXO1 in fusion-positive rhabdomyosarcoma.Nature communications · 2024Article
- EBF2 Links KMT2D-Mediated H3K4me1 to Suppress Pancreatic Cancer Progression via Upregulating KLLN.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Targeted Therapy for EWS-FLI1 in Ewing Sarcoma.Cancers · 2023Review
- Pharmacological inhibition of LSD1 suppresses growth of hepatocellular carcinoma by inducing GADD45B.MedComm · 2023Article
- Article
- Regulation of EWSR1-FLI1 Function by Post-Transcriptional and Post-Translational Modifications.Cancers · 2023Review
- Primary mediastinal Ewing's sarcoma presenting with sudden and severe chest pain: a case report.Frontiers in oncology · 2023Article
- CircRANBP17 modulated KDM1A to regulate neuroblastoma progression by sponging miR-27b-3p.Open medicine (Warsaw, Poland) · 2023Article
- Ewing Sarcoma Meets Epigenetics, Immunology and Nanomedicine: Moving Forward into Novel Therapeutic Strategies.Cancers · 2022Review
- Salinomycin suppresses T24 cells by regulating KDM1A and the unfolded protein response pathway.Cytotechnology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 10 institutions in 5 countries.
Kathleen I PishasCancer Therapeutics Laboratory, Discipline of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
Christina D DrenbergDivision of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, Ohio.ORCID 0000-0001-7759-8213
Cenny TaslimCenter for Childhood Cancer and Blood Disorders, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio.ORCID 0000-0003-3302-9099
Emily R TheisenCenter for Childhood Cancer and Blood Disorders, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio.
Kirsten M JohnsonCenter for Childhood Cancer and Blood Disorders, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio.
Ranajeet S SaundCenter for Childhood Cancer and Blood Disorders, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio.
Ioana L PopHuntsman Cancer Institute, School of Medicine, University of Utah, Salt Lake City, Utah.
Brian D CromptonDepartment of Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.
Elizabeth R LawlorDepartment of Pediatrics and Communicable Diseases, University of Michigan Medical School, Ann Arbor, Michigan.ORCID 0000-0002-2350-1540
Franck TirodeUniv Lyon, Universite Claude Bernard Lyon, Centre Leon Berard, Cancer Research Center of Lyon, Lyon, France.ORCID 0000-0003-4731-7817
Jaume MoraDepartment of Pediatric Hemato-Oncology, Hospital Sant Joan de Déu, Barcelona, Spain.ORCID 0000-0001-5023-9819
Olivier DelattreInstitut Curie, PSL Research University, Service de Genetique, Pole de Medecine Diagnostique et Theranostique, Unité de Génétique Somatique, Paris, France.
Mary C BeckerleHuntsman Cancer Institute, School of Medicine, University of Utah, Salt Lake City, Utah.ORCID 0000-0001-9176-4724
David F CallenCancer Therapeutics Laboratory, Discipline of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
Sunil SharmaTGen Clinical Sciences, Applied Cancer Research and Drug Discovery, Phoenix, Arizona.
Stephen L LessnickCenter for Childhood Cancer and Blood Disorders, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio. Stephen.Lessnick@nationwidechildrens.org.
Nationwide Children's Hospital · USHuntsman Cancer Institute · USDrug Discovery Laboratory (Norway) · NOExpression Génétique Microbienne · FRHarvard University · USHospital Sant Joan de Déu Barcelona · ESThe Ohio State University · USThe University of Adelaide · AUUniversité Claude Bernard Lyon 1 · FRUniversity of Michigan · US
Funding
NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6MCOG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8MTranslational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3MUTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6MSupport for Human Specimen Banking in NCI-Supported Cancer Clinical TrialsU24CA114766 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI RAMIREZ MILAN, NILSA DEL CARMEN · 2005 to 2014
$14.5MEWS/FLI AND ITS TARGETS IN EWING'S SARCOMAR01CA140394 · NCI · UNIVERSITY OF UTAH · PI LESSNICK, STEPHEN L. · 2010 to 2014
$1.5M(PQB-2) "Driver" vs. "passenger" epigenetic events in Ewing sarcomaR01CA183776 · NCI · UNIVERSITY OF UTAH · PI LESSNICK, STEPHEN L., SHARMA, SUNIL · 2014 to 2017
$1.2MTargeting FAK and integrin signaling in preclinical models of Ewing sarcomaK08CA188073 · NCI · DANA-FARBER CANCER INST · PI CROMPTON, BRIAN · 2015 to 2019
$886kNCI NIH HHS K08 CA188073NCI NIH HHS P30 CA016058NCI NIH HHS P30 CA042014NCI NIH HHS R01 CA140394NCI NIH HHS R01 CA183776NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899NCI NIH HHS U24 CA114766
Abstract
Multi-agent chemotherapeutic regimes remain the cornerstone treatment for Ewing sarcoma, the second most common bone malignancy diagnosed in pediatric and young adolescent populations. We have reached a therapeutic ceiling with conventional cytotoxic agents, highlighting the need to adopt novel approaches that specifically target the drivers of Ewing sarcoma oncogenesis. As KDM1A/
Indexed as
AdolescentApoptosisBone NeoplasmsCell Line, TumorChildEndoplasmic Reticulum StressEnzyme InhibitorsGene Expression Regulation, NeoplasticHistone DemethylasesHumansRNA InterferenceSarcoma, EwingSignal TransductionSmall Molecule LibrariesEnzyme InhibitorsHistone DemethylasesKDM1A protein, humanSmall Molecule Libraries
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.